/
OMCL
$41.52+$0.60 (+1.47%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$1.8B
45M shares
52-week range
$26.85 – $55.00
52% from low
Sector
ELECTRONIC COMPUTERS
Exchange
NASDAQ
CS
Borrow rate
0.29%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-107.17
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $787.3M | $897.0M | $892.2M | $1.13B | $1.30B | $1.15B | $1.11B | $1.18B |
| Cost of revenue | $415.0M | $460.1M | $478.9M | $577.4M | $707.0M | $647.2M | $641.2M | $676.8M |
| Gross profit | $372.3M | $436.9M | $413.3M | $554.7M | $589.0M | $499.9M | $471.0M | $508.0M |
| Gross margin | 47.3% | 48.7% | 46.3% | 49.0% | 45.4% | 43.6% | 42.3% | 42.9% |
| R&D | $64.8M | $68.6M | $70.2M | $75.7M | $105.0M | $93.3M | $90.4M | $87.7M |
| Operating income | $44.4M | $78.4M | $35.5M | $89.5M | −$2.3M | −$19.3M | $337.0K | $11.7M |
| EBITDA | $95.7M | $142.5M | $107.1M | $173.3M | $96.8M | $80.0M | $119.9M | $101.9M |
| Net income | $37.7M | $61.3M | $32.2M | $77.8M | $5.6M | −$20.4M | $12.5M | $2.1M |
| Net margin | 4.8% | 6.8% | 3.6% | 6.9% | 0.4% | -1.8% | 1.1% | 0.2% |
| EPS (diluted) | 0.93 | 1.43 | 0.74 | 1.62 | 0.12 | -0.45 | 0.27 | 0.04 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.2B | $1.94 | $1.91–$1.95 | 5 |
| 2027 | $1.3B | $2.19 | $2.01–$2.52 | 5 |
| 2028 | $1.4B | $2.30 | $2.26–$2.34 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$27.03
Price
$41.52
Implied downside
-35%
Peer comparison
Omnicell Inc
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
www.omnicell.com- Employees
- 3,525
- IPO / List date
- Aug 6, 2001
- HQ
- FORT WORTH, TX
Held by traders on TradeandTell
No one on the platform currently holds OMCL.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 483,043 | $16.1M |
| Bridgewater Associatesas of 2024-12-31 | 4,959 | $220.8K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded OMCL yet.
